Silk Road Medical, Inc. (SILK)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Silk Road Medical, Inc. ("Silk Road" or the "Company") (NASDAQ: SLK).  The investigation concerns whether Silk Road and certain of its officers and/or directors have violated federal securities laws.


On January 13, 2021, Silk Road announced in a U.S. Securities and Exchange Commission filing that the Company was “voluntarily recalling 288 units of our ENROUTE® Transcarotid Stent System, or ENROUTE SDS, based on five reports we received related to the tip of the stent delivery system becoming detached in five TCAR procedures.  These reports were made between September 2020 and January 2021 and we have commenced an investigation into this matter.”  On this news, Silk Road’s stock price fell $4.22 per share, or 7.12%, to close at $55.02 per share on January 13, 2021.


If you are aware of any facts relating to this investigation, or purchased Silk Road shares, you can assist this investigation by visiting contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.